Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Microbiome
Sort By
Newest First
1 / 3
1 / 3
Microbiome
Modifying the Gut Microbiome to Improve CAR-T, HSCT, and Other Therapeutic Responses
Stacy Burns-Guydish, Ph.D.
List Labs
PAO-10-23-CL-07-33
November 01, 2023
Microbiome Therapeutic Innovation
Unleashing the Power of the Microbiome: Advancements, Challenges, and the Therapeutic Future
Stacy Burns-Guydish, Ph.D.; Gary Henderson
List Labs
PAO-03-23-CL-08
April 04, 2023
Microbiome-Based CDMO
Expanding a Leadership Position in Microbiome-Based Contract Development and Manufacturing
Stacy Burns-Guydish, Ph.D.; Jonathan Yongwan Jo; Gary Henderson; Michael Kimble
List Labs
PAO-11-022-CL-13
December 13, 2022
Diabetes Research
Composition of Gut Microbiome Predicts the Onset of Type 2 Diabetes
University of Turku
PR-M02-22-13
February 16, 2022
Live Biotherapeutic Products
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
Aaron B. Cowley, Ph.D.; Nicole O'Brien, Ph.D.
Arranta Bio
PAO-09-21-CL-11
September 28, 2021
Live Biotherapeutic Products
Design Considerations for Live Biotherapeutic Product Facilities Working with Spore-Forming Bacteria
Aaron B. Cowley, Ph.D.; Judith Bodette; Brian Duffy
Arranta Bio
PAO-06-21-CL-10
June 25, 2021
Live Biotherapeutic Products
Framing the Narrative on CMC Development for Microbiome Therapeutics
Aaron B. Cowley, Ph.D.; Melanie Cerullo; Jeff Heiser
Arranta Bio
PAO-06-21-CL-05
June 14, 2021
Microbiome
Understanding the Link Between Gut Health and Disease
Dr. Sabine Hazan
ProgenaBiome
PTV-05-21-CL-004
May 27, 2021
COVID-19 Impacts
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
Pharma's Almanac
PAO-03-21-NI-01
March 16, 2021
Manufacturing Facility
Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and Closes Series B Equity Financing
ArrantaBio
PR-M03-21-002-1066
March 08, 2021
Corporate Social Responsibility
Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity
Susan Surabian; Melanie Cerullo
Arranta Bio
PAP-Q4-20-CL-002
December 09, 2020
The Future of Healthcare
How Does Arranta Bio Envision the Future of the Pharma/Biopharma Industry?
Arranta Bio
PAP-Q4-20-RT2-007
December 09, 2020
Gene Editing
Enhancing Human Gut Tissue Models through Gene Editing
Scott Magness, Ph.D.
Altis Biosystems
PAO-11-20-CL-03
November 30, 2020
Microbiome
Evaluating Microbiome Therapies with Intestinal Cell Models
Scott Magness, Ph.D.
Altis Biosystems
PAO-10-20-CL-02
October 22, 2020
Microbiome CDMO
Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products
Aaron B. Cowley, Ph.D.
Arranta Bio
PAP-Q3-20-CL-004
September 29, 2020
Design Logic
Experience to Solve Your Microbiome Challenges
Nice Insight
PAP-Q3-20-NI-010
September 29, 2020
The Future of Healthcare
How Is Arranta Bio Evolving its Business Model to Meet the Future of Healthcare?
Arranta Bio
PAP-Q3-20-RT2-009
September 29, 2020
Microbiome
Selecting a Microbiome CDMO Partner for the Long Term
Dave Stevens; Jason Rahal
Arranta Bio
PAP-Q2-20-CL-008
July 01, 2020
Microbiome
Reflections on a 10-Year Journey in the Microbiome
Aaron B. Cowley, Ph.D.
Arranta Bio
PAP-Q1-20-CL-006
March 19, 2020
Microbiota
Proving the Link Between the Microbiota and the Human Immune System in Non-Human Primates
Hugues Contamin, DVM, Ph.D.
Cynbiose
PAP-Q1-20-CL-021
March 19, 2020
